Perceptions of patient disease burden and management approaches in systemic mastocytosis: Results of the TouchStone Healthcare Provider Survey.
Ruben A MesaErin M SullivanDavid DubinskiBrittany CarrollValerie M SleeSusan V JenningsCeleste C FinnertyLinda S BohannonSusan D MathiasBetsy J LahueMariana C CastellsPublished in: Cancer (2022)
Specialists treating systemic mastocytosis (SM) completed a 51-item questionnaire about their clinical practices and perceptions of disease impact. The study included 111 hematology, oncology, allergy, and immunology physicians. Physicians reported that most patients had nonadvanced disease, yet SM symptoms significantly disrupted their patients' lives. Physicians estimated that SM is diagnosed within months of symptom onset, in contrast with published reports of years' long delays reported by patients with SM. This study identified unmet needs that can inform educational and patient management priorities in this rare disease.
Keyphrases
- primary care
- healthcare
- end stage renal disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- palliative care
- case report
- magnetic resonance imaging
- patient reported
- randomized controlled trial
- cross sectional
- patient reported outcomes
- computed tomography
- social media
- depressive symptoms
- health insurance
- functional connectivity
- health information
- infectious diseases
- resting state